Keep up with everything going on in the pulmonary hypertension community with news, stories, events, educational information and ways to get involved.
Monday, June 16, 2014
News: Possible New Type of Targeted Therapy for Pulmonary Hypertension
Reuters - Actelion Pharmaceuticals US, Inc. released today the initial, positive results from the Phase III GRIPHON study of selexipag in 1,156 patients with pulmonary arterial hypertension (PAH). Selexipag is the first non-prostacyclin analogue that acts as a stimulator for the prostaglandin receptor (IP).